BlueScope is currently weighing a takeover proposal from a consortium backed by an industrial player and an investment group at a time when its share price is under pressure and sentiment has turned cautious after its latest earnings result. The local business faces added uncertainty from potential US tariffs linked to shifting trade policies, which some investors fear could drag the stock lower over coming months if the deal stalls or fails.
In the background, at least two large global private equity funds with core-plus infrastructure strategies recently looked at a competing offer focused only on BlueScope’s North American operations rather than the entire company. These funds were said to be open to buying the whole group and then selling the Australian operations back to the current bidding consortium, but only if that buyer paid more for the domestic assets. This suggests they see extra value in the US arm compared with the rest of the portfolio. While most market watchers still see the odds of a formal rival bid as low, the interest alone is shaping how advisers think about the company’s defence.
BlueScope has sent a detailed letter to the consortium asking them to break out how much of their bid value they attribute to the North American business versus the rest of the world operations, a breakdown the bidders have so far avoided providing. Some investors believe this request is not just about transparency, it could also help BlueScope’s advisers benchmark the current offer and test demand from other buyers for the US assets, effectively mapping out what a competing North America-only proposal would need to look like to beat the existing $34-per-share headline price. The consortium has labelled its revised bid “best and final”, which under market convention locks the offer for six months unless a rival proposal emerges, but BlueScope’s board argues the effective value is closer to $31 per share once upcoming dividends are taken into account and is probing the structure in a way that might allow minor adjustments without technically breaching that “best and final” stance.
This all plays into a bigger strategic game that seems to be forming around timing and market mood. One path for the bidding consortium is simply to wait out the six-month period and return later, especially if tariffs and weaker sentiment push BlueScope’s share price down from its recent close of $27.71, already 2.3% lower on the day. Large shareholders appear divided, with one major local fund now encouraging engagement with the bidders while other institutional investors have been buying more stock. Many interpret this buying as a sign that these investors expect a deal to happen and want exposure to any takeover premium. With potential private equity interest in the US arm, a “best and final” offer that might not be as final as it sounds and a softening share price, the next few months look likely to determine whether BlueScope stays whole, is partially carved up or is taken over on different terms than those currently on the table.
